HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV, according to a study published online March ...

HIV-1 reverse transcriptase inhibitors remain a cornerstone of antiretroviral therapy, targeting the enzyme responsible for converting viral RNA into DNA. This class of drugs, particularly nucleoside ...

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

Clin Drug Invest. 2007;27(8):509-531. Antiretroviral drugs (ARVs) can be divided into four different classes according to their modes of action: nucleoside or nucleotide reverse transcriptase ...

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- ROME Therapeutics, a biotechnology company illuminating the intersection of the dark genome and innate immunity to develop breakthrough medicines for ...

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...

New England Biolabs (NEB®) announced today that they have released a novel, thermostable reverse transcriptase, WarmStart® RTx Reverse Transcriptase, specifically designed for nucleic acid detection.

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...